Publications of J. Bange

Roidl, A.; Berger, H. J.; Kumar, S.; Bange, J.; Knyazev, P.; Ullrich, A.: Resistance to Chemotherapy Is Associated with Fibroblast Growth Factor Receptor 4 Up-Regulation. Clinical Cancer Research 15 (6), pp. 2058 - 2066 (2009)

Thussbas, C.; Nahrig, J.; Streit, S.; Bange, J.; Kriner, M.; Kates, R.; Ulm, K.; Kiechle, M.; Hoefler, H.; Ullrich, A. et al.; Harbeck, N.: FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. Journal of Clinical Oncology 24 (23), pp. 3747 - 3755 (2006)

Stadler, C. R.; Knyazev, P.; Bange, J.; Ullrich, A.: FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. Cellular Signalling 18 (6), pp. 783 - 794 (2006)

Abraham, R.; Schafer, J.; Rothe, M.; Bange, J.; Knyazev, P.; Ullrich, A.: Identification of MMP-15 as an anti-apoptotic factor in cancer cells. Journal of Biological Chemistry 280 (40), pp. 34123 - 34132 (2005)

Berger, I. R.; Buschbeck, M.; Bange, J.; Ullrich, A.: Identification of a transcriptionally active hVH-5 pseudogene on 10q22-2. Cancer Genetics and Cytogenetics 159 (2), pp. 155 - 159 (2005)

Streit, S.; Bange, J.; Fichtner, A.; Ihrler, S.; Issing, W.; Ullrich, A.: Involvement of the FGFr4 Arg388 allele in head and neck squamous cell carcinoma. International Journal of Cancer 111 (2), pp. 213 - 217 (2004)

Bange, J.; Prechtl, D.; Cheburkin, Y.; Specht, K.; Harbeck, N.; Schmitt, M.; Knyazeva, T.; Müller, S.; Gärtner, S.; Sures, I. et al.; Wang, H. Y.; Imyanitov, E.; Haring, H. U.; Knayzev, P.; Iacobelli, S.; Hofler, H.; Ullrich, A.: Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Research 62 (3), pp. 840 - 847 (2002)

Zwick, E.; Bange, J.; Ullrich, A.: Receptor tyrosine kinases as targets for anticancer drugs. Trends in Molecular Medicine 8 (1), pp. 17 - 23 (2002)

Thussbas, C.; Nahrig, J.; Streit, S.; Bange, J.; Kates, R.; Ulm, K.; Kiechle, M.; Hoefler, H.; Ullrich, A.; Harbeck, N.: FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. ASCO Annual Meeting, 2006. Meeting Abstracts, p. 34S - 34S (2006)